Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on
overall survival in newly diagnosed elderly patients with glioblastoma.
Who is it for? You may be eligible to join this study if you are aged 65 years or above, with
newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma)
following surgery.
The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide
improves overall survival outcomes for this patient population. The outcome of the study will
help determine the most effective treatment for patients with glioblastoma in the future.
Phase:
Phase 2
Details
Lead Sponsor:
University of Sydney
Collaborators:
Cooperative Trials Group for Neuro-Oncology National Health and Medical Research Council, Australia